Graft-versus-host disease (GVHD) after liver transplantation is rare but associated with a very high mortality (over 85%). Most treatments focus on increasing immunosuppression, addition of antibody preparations such as OKT3 and antithymocyte globulin to eliminate the donor lymphocytes, and supporti
Immunopathogenesis of Acute Graft-versus-Host Disease: Implications for Novel Preventive and Therapeutic Strategies
โ Scribed by Robert Zeiser; Reinhard Marks; Hartmut Bertz; Juergen Finke
- Publisher
- John Wiley and Sons
- Year
- 2005
- Weight
- 8 KB
- Volume
- 36
- Category
- Article
- ISSN
- 0931-7597
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
CHOP, COP plui doxorubicin. ,'According to NCI criteria (Cheson el al. 151). (PD) was registered in one patient. Median time to disease progression for patients in PR or SD was 9 months (range, 1-14 months) (Table I). The results of the prehent study, although based on a small number of patients,
Staging System and chromosomal abnormalities determined by standard metaphase karyotype and/or fluorescence in situ hybridization (FISH). Treatment-induced adverse events were graded according to the National Cancer Institute common terminology criteria for adverse events (CTCAE) version 4.0. For r
Patients undergoing bone marrow transplantation are at high risk of developing acute graft-versus-host disease (GVHD) which is a primary limiting factor for this procedure inasmuch as it is responsible for high morbidity rates and is associated with poor survival outcome. To provide improved treatme
We introduce a novel application for linkage analysis: using bone marrow donorrecipient sib pairs to search for genes influential in graft-versus-host disease (GVHD), a major cause of morbidity and mortality following allogeneic bone marrow transplantation. In particular, we show that transplant sib